French Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Novacyt

Market Cap: €33.2m

Develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors.

TME Pharma

Market Cap: €9.3m

A clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.

DBV Technologies

Market Cap: €210.1m

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Aelis Farma

Market Cap: €14.9m

A clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.

Sanofi

Market Cap: €94.3b

Engages in the research, development, manufacture, and marketing of therapeutic solutions.

Boiron

Market Cap: €507.0m

Manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

Ipsen

Market Cap: €9.2b

Operates as a biopharmaceutical company worldwide.

Virbac

Market Cap: €2.6b

Manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific.

Eurobio Scientific Société anonyme

Market Cap: €254.4m

Engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer.

OSE Immunotherapeutics

Market Cap: €137.5m

A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.

Sensorion

Market Cap: €93.5m

A biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.

Valbiotis

Market Cap: €12.9m

Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France.

Vetoquinol

Market Cap: €898.8m

A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.

Genfit

Market Cap: €151.9m

A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

Neovacs

Market Cap: €87.5k

A biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.

Cellectis

Market Cap: €214.4m

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

Eurofins-Cerep

Market Cap: €91.8m

Provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally.

Valneva

Market Cap: €741.9m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

ABIONYX Pharma

Market Cap: €132.6m

A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.

Eurofins Scientific

Market Cap: €10.8b

Provides various analytical testing and laboratory services worldwide.

Euroapi

Market Cap: €279.0m

Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

genOway Société anonyme

Market Cap: €29.3m

A biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide.

MaaT Pharma

Market Cap: €63.3m

A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.

Innate Pharma

Market Cap: €149.3m

Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.